Results 41 to 50 of about 566,656 (110)

Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Years' Follow-Up

Journal of Clinical Oncology, 2021
PURPOSE APHINITY, at 45 months median follow-up, showed that pertuzumab added to adjuvant trastuzumab and chemotherapy significantly improved invasive disease–free survival (IDFS) (hazard ratio 0.81 [95% CI, 0.66 to 1.00], P = .045) for patients with ...
M. Piccart, M. Procter, D. Fumagalli, E. de Azambuja, E. Clark, M. Ewer, E. Restuccia, G. Jerusalem, S. Dent, L. Reaby, H. Bonnefoi, I. Krop, Tsang W. Liu, T. Pieńkowski, M. Toi, N. Wilcken, M. Andersson, Y. Im, Ling-Ming Tseng, H. Lueck, M. Colleoni, E. Monturus, Mihaela Sicoe, S. Guillaume, J. Bines, R. Gelber, G. Viale, C. Thomssen   +27 more
semanticscholar   +1 more source

Molecular Classification of the PORTEC-3 Trial for High-Risk Endometrial Cancer: Impact on Prognosis and Benefit From Adjuvant Therapy

Journal of Clinical Oncology, 2020
PURPOSE The randomized Adjuvant Chemoradiotherapy Versus Radiotherapy Alone in Women With High-Risk Endometrial Cancer (PORTEC-3) trial investigated the benefit of combined adjuvant chemotherapy and radiotherapy (CTRT) versus radiotherapy alone (RT) for ...
A. Léon-Castillo, S. D. de Boer, M. Powell, L. Mileshkin, H. Mackay, A. Leary, H. Nijman, Naveena Singh, P. Pollock, P. Bessette, A. Fyles, C. Haie-meder, V. Smit, R. Edmondson, H. Putter, H. Kitchener, E. Crosbie, M. de Bruyn, R. Nout, N. Horeweg, C. Creutzberg, T. Bosse   +21 more
semanticscholar   +1 more source

Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a phase 3, open-label, randomised controlled trial

The Lancet, 2020
Summary Background Urothelial carcinomas of the upper urinary tract (UTUCs) are rare, with poorer stage-for-stage prognosis than urothelial carcinomas of the urinary bladder.
A. Birtle, Mark Johnson, J. Chester, Robert J. Jones, D. Dolling, R. Bryan, Christopher Harris, A. Winterbottom, A. Blacker, J. Catto, P. Chakraborti, J. Donovan, P. A. Elliott, A. French, S. Jagdev, B. Jenkins, F. Keeley, R. Kockelbergh, T. Powles, J. Wagstaff, Caroline Wilson, R. Todd, Rebecca Lewis, E. Hall   +23 more
semanticscholar   +1 more source

The chemotherapeutic agent DMXAA as a unique IRF3-dependent type-2 vaccine adjuvant [PDF]

, 2013
5,6-Dimethylxanthenone-4-acetic acid (DMXAA), a potent type I interferon (IFN) inducer, was evaluated as a chemotherapeutic agent in mouse cancer models and proved to be well tolerated in human cancer clinical trials.
Cevayir Coban, Kenji Mizuguchi, Junichi Ito, Etsushi Kuroda, Coban, C, Ishii, KJ, Choon Kit Tang, Shizuo Akira, Jounai, N, Benoit H Dessailly, Ito, J, Keiichi Ohata, Tang, CK, Akira, S, Mizuguchi, K, Ken J Ishii, Kouji Kobiyama, Ohata, K, Nao Jounai, Kuroda, E, Kobiyama, K, Dessailly, BH, Aoshi, T, Taiki Aoshi, Mizuguchi Kenji, Tang Choon Kit, Aoshi Taiki, Jounai Nao, Ishii Ken J., Ito Junichi, Akira Shizuo, Dessailly Benoit H., Kuroda Etsushi, Ohata Keiichi, Kobiyama Kouji, Coban Cevayir   +35 more
core   +1 more source

Adjuvant or early salvage radiotherapy for the treatment of localised and locally advanced prostate cancer: a prospectively planned systematic review and meta-analysis of aggregate data

The Lancet, 2020
Summary Background It is unclear whether adjuvant or early salvage radiotherapy following radical prostatectomy is more appropriate for men who present with localised or locally advanced prostate cancer. We aimed to prospectively plan a systematic review
C. Vale, D. Fisher, A. Kneebone, C. Parker, M. Pearse, P. Richaud, P. Sargos, M. Sydes, C. Brawley, M. Brihoum, C. Brown, S. Chabaud, A. Cook, S. Forcat, C. Fraser-Browne, I. Latorzeff, M. Parmar, J. Tierney   +17 more
semanticscholar   +1 more source

Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial.

The Lancet, 2017
BACKGROUND The ESPAC-3 trial showed that adjuvant gemcitabine is the standard of care based on similar survival to and less toxicity than adjuvant 5-fluorouracil/folinic acid in patients with resected pancreatic cancer.
J. Neoptolemos, D. Palmer, P. Ghaneh, E. Psarelli, J. Valle, C. Halloran, O. Faluyi, D. O'Reilly, D. Cunningham, J. Wadsley, S. Darby, T. Meyer, R. Gillmore, A. Anthoney, P. Lind, B. Glimelius, S. Falk, J. Izbicki, G. Middleton, S. Cummins, P. Ross, H. Wasan, A. Mcdonald, T. Crosby, Yuk-Ting Ma, K. Patel, David Sherriff, R. Soomal, D. Borg, S. Sothi, P. Hammel, T. Hackert, R. Jackson, M. Büchler   +33 more
semanticscholar   +1 more source

Deneysel romatoid artritte ozon uygulamasının artrit şiddeti ve DNA hasarına etkisi

, 2023
ÖZETAmaç: Romatoid artrit (RA) patogenezinde rol oynayan faktörlerden birisi de oksidatif strestir. Ozon,güçlü oksitleyici etkisinin yanı sıra vücutta antioksidan mekanizmaları tetikleyici etkisi olan birgazdır.
Mazlum, Kübra, Yüksel, Pınar, Yavuz, Başak, Edremitlioğlu, Mustafa, Türkön, Hakan, Demir, Ufuk, Zateri, Coşkun   +6 more
core  

Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer

New England Journal of Medicine, 2018
BACKGROUND The recurrence score based on the 21‐gene breast cancer assay predicts chemotherapy benefit if it is high and a low risk of recurrence in the absence of chemotherapy if it is low; however, there is uncertainty about the benefit of chemotherapy
J. Sparano, R. Gray, D. Makower, K. Pritchard, K. Albain, D. Hayes, C. Geyer, E. Dees, M. Goetz, J. Olson, T. Lively, S. Badve, T. Saphner, L. Wagner, T. Whelan, M. Ellis, S. Paik, W. Wood, P. Ravdin, M. Keane, H. G. Gomez Moreno, Pavan S. Reddy, T. Goggins, I. Mayer, A. Brufsky, D. Toppmeyer, V. Kaklamani, J. Berenberg, J. Abrams, G. Sledge   +29 more
semanticscholar   +1 more source

Diabetes alone should not be a reason for withholding adjuvant chemotherapy for stage III colon cancer [PDF]

, 2011
Background: With increasing prevalence of diabetes mellitus and colon cancer, the number of patients suffering from both diseases is growing, and physicians are being faced with complicated treatment decisions.
Wouter M. W. Dercksen, Extermann, Martine, Harm R. Haak, Janssen-Heijnen, Maryska L.G., van de Schans, Saskia A.M., Haak, Harm R., Dercksen, Wouter M.W., Maren A. van Waalwijk, Martine Extermann, van Waalwijk, Maren A., Saskia A. M. van de Schans, Maryska L. G. Janssen-Heijnen, Janssen-Heijnen, Dr Maryska, Dercksen, Wouter M., Waalwijk, Maren A., Schans, Saskia A.   +15 more
core   +1 more source

Deneysel artrit modelinde silymarin ile tedavinin etkisi [PDF]

, 2018
Adjuvant artrit, hücresel immün yanıtla oluşması ve histopatolojik görünümlerinin benzerliği nedeniyle romatoid artrit modeli olarak sıklıkla kullanılmaktadır.
Ürek, Özlem
core   +1 more source